Quanterix

Quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. Quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN).

Type
Private
HQ
Lexington, US
Founded
2007
Employees
108 (est)+4%
Quanterix was founded in 2007 and is headquartered in Lexington, US

Key People at Quanterix

Paul Chapman

Paul Chapman

President & CEO & Board Director
Paul M. Meister

Paul M. Meister

Director
David Duffy, Ph.D.

David Duffy, Ph.D.

CTO & VP, Research
Julien Bradley

Julien Bradley

Senior Director, Sales & Marketing
David H. Wilson

David H. Wilson

VP, Product Development
James Drummey

James Drummey

Senior Director, Manufacturing Operations

Quanterix Locations

Lexington, US
New York, US
Philadelphia, US
Austin, US
Baltimore, US
San Diego, US
San Francisco, US
Boston, US

Quanterix Metrics

Quanterix Summary

Founding Date

2007

Total Funding

$69.5 M

Latest funding size

$46 M

Time since last funding

10 months

Investors

We estimate that Quanterix's latest funding round in March 2016 was $46 M. In total, Quanterix has raised $69.5 M
We estimate that Quanterix's current employees are approximately 11% female and 89% male.

Quanterix Online Presence

Quanterix Company Life

You may also be interested in